Novel Orally-Active Kinase Inhibitor Induces Tumor Regression In Multiple Preclinical Models

EntreMed, Inc.
(Nasdaq: ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases,
announced the presentation of preclinical results for its multi-target
kinase inhibitor, ENMD-981693. The data were presented by EntreMed
scientists at the 48th Annual Meeting of the American Society of Hematology
(ASH) being held December 9-12, 2006 in Orlando, Florida.



ENMD-981693 is a multi-target kinase inhibitor with a unique
selectivity profile and multiple mechanisms of action, including
antiproliferative activity and the inhibition of angiogenesis. In
preclinical studies, ENMD- 981693 has been shown to inhibit a unique
profile of tyrosine kinase targets, in addition to the Aurora kinases.
ENMD-981693 is selective for Aurora A in comparison to Aurora B. Aurora
kinases are key regulators of the process of mitosis or cell division, and
are often over-expressed in human cancers.



ENMD-981693 has shown highly potent activity against oncogenic receptor
tyrosine kinases and cytoplasmic tyrosine kinases in vitro. ENMD-981693
induces cell cycle arrest and apoptosis in a wide variety of cell lines.
ENMD-981693 inhibits the activity of multiple kinases in vitro, including
FLT3, c-Kit and CSF1R, which are involved in hematological cancers.
Additionally, the compound demonstrated potent activity towards a broad
spectrum of targets linked to angiogenesis and lymphangiogenesis (lymphatic
vessels), including KDR (VEGFR2).



In results from in vivo animal models, ENMD-981693 exhibited anti-
angiogenic activity by preventing the formation of new blood vessels and
inducing regression of formed vessels at well-tolerated doses. ENMD-981693
induced strong tumor regression with minimal toxic effects when
administered orally in animal models bearing tumors from a human leukemia
cell line. This activity is consistent with tumor regression induced by
ENMD-981693 in animal models of human tumors derived from leukemia, colon,
and breast cancer cell lines with minimal toxicity.



Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief
Medical Officer, commented, "ENMD-981693 is a novel, orally-active,
multi-kinase inhibitor with potent antiproliferative and antiangiogenic
activity. In addition, ENMD-981693 has been shown to induce tumor
regression at well- tolerated doses in multiple animal models. These data
supported the selection of ENMD-981693 as a clinical development candidate
in our kinase inhibitor program."



Dr. Sidor commented further, "Based on the potent preclinical activity
of this compound and its ability to target multiple kinases, we believe
that ENMD-981693 may be suitable for use in a variety of hematological and
solid cancers. We are currently conducting IND-enabling studies for this
compound in anticipation of filing an IND in 2007."
















To view the poster presentation, visit Scientific Presentations under
the Therapeutic Pathways section of the Company's web site at entremed/.



About EntreMed



EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical
company developing therapeutic candidates primarily for the treatment of
cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the
Company's lead drug candidate, is currently in Phase 1 and 2 clinical
trials for cancer, as well as in preclinical development for rheumatoid
arthritis. MKC-1, an oral cell cycle regulator, is in Phase 1 and 2
clinical trials for cancer. ENMD-1198, a novel tubulin binding agent, is
also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop
and commercialize new compounds based on the Company's expertise in
angiogenesis, cell cycle regulation, signaling pathways, and inflammation -
processes vital to the treatment of cancer and other diseases, such as
rheumatoid arthritis. Additional information about EntreMed is available on
the Company's website at entremed/ and in various filings
with the Securities and Exchange Commission.



Forward Looking Statements



This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act with respect to the outlook
for expectations for future financial or business performance (including
the timing of royalty revenues and future R&D expenditures), strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and no
duty to update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number of
factors, including those set forth in Securities and Exchange Commission
filings under "Risk Factors," including risks relating to the need for
additional capital and the uncertainty of additional funding; variations in
actual sales of Thalomid(R), risks associated with development of product
candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical results;
uncertainties relating to preclinical and clinical trials; success in the
clinical development of any products; dependence on third parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).


EntreMed, Inc.

entremed/